A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Biliary Cholangitis
Latest Information Update: 28 Aug 2024
At a glance
- Drugs Volixibat (Primary)
- Indications Primary biliary cirrhosis
- Focus Registrational; Therapeutic Use
- Acronyms VANTAGE
- Sponsors Mirum Pharmaceuticals
- 17 Jun 2024 According to a Mirum Pharmaceuticals media release, based on interim analysis the trial will continue with a volixibat dose of 20 mg twice daily.
- 17 Jun 2024 According to a Mirum Pharmaceuticals media release, the company to host a conference call to discuss a interim analysis of VISTAS and VANTAGE on Monday, June 17 at 8:30 a.m. ET/5:30 a.m. Kris Kowdley is investigator in this trial.
- 17 Jun 2024 Interim results presented in the Mirum Pharmaceuticals Media Release.